首页> 外文期刊>Inhalation toxicology >The in vitro and in vivo investigation of a novel small chamber dry powder inhalation delivery system for preclinical dosing to rats
【24h】

The in vitro and in vivo investigation of a novel small chamber dry powder inhalation delivery system for preclinical dosing to rats

机译:新型小室干粉吸入输送系统的临床和体外给药研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose: This research describes a novel minitower dry powder delivery system for nose-only delivery of dry powder aerosols to spontaneously breathing rats.Methods: The minitower system forces pressurized air through pre-filled capsules to deliver aerosolized drug to four nose ports; three of which house spontaneously breathing rats, with the fourth used as a control. Within each port are vent filters which capture drug that was not inhaled for further quantitation. These vent filters along with a novel control system referred to as the artificial rat lung, allow for the theoretical amount of drug delivered and subsequently inhaled by each rat to be calculated.Results: In vitro and in vivo studies have demonstrated this system's ability to deliver aerosolized drug to rats. The in vitro study showed that approximate to 30% of the starting dose reached the 4 ports and was available for inhalation. During in-vivo studies, rats inhaled approximate to 34% of the delivered dose. Of the estimated inhaled dose, 12-18% was detectable in the various tissue samples, with over 30% of the recovered dose found in the rat's lungs.Conclusion: Results show that this system is capable of reproducibly delivering drug to the lungs of spontaneously breathing rats. Advantages over current delivery methods include being amenable to the administration of multiple doses and using less (milligram) amount of starting material. In addition, this technique avoids anesthesia which is typically required for instillation or insufflation, and thus has the potential as an efficient and noninvasive aerosol delivery method for preclinical drug development.
机译:目的:本研究描述了一种新型的小型塔式干粉输送系统,该系统仅用于将鼻腔内的干粉气溶胶仅输送至自发呼吸的大鼠。方法:小型塔式系统迫使加压空气通过预填充的胶囊将雾化药物输送至四个鼻孔;其中三只自发地呼吸大鼠,第四只用作对照组。每个端口内都有排气过滤器,用于捕获未吸入的药物以进行进一步定量。这些通气过滤器与称为人工大鼠肺的新型控制系统一起,可以计算出每只大鼠理论上释放并随后吸入的药物量。结果:体外和体内研究证明了该系统的释放能力雾化药物给大鼠。体外研究表明,约有起始剂量的30%到达4个端口,可用于吸入。在体内研究中,大鼠吸入了大约34%的给药剂量。在估计的吸入剂量中,在各种组织样本中可检测到12-18%,在大鼠的肺中发现的回收剂量超过30%。结论:结果表明,该系统能够可重复地将药物自发地输送到肺部呼吸的老鼠。相对于当前的递送方法的优点包括适合于多剂量的施用和使用较少(毫克)量的原料。另外,该技术避免了滴注或吹入通常需要的麻醉,因此具有作为用于临床前药物开发的有效且无创的气雾剂递送方法的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号